NASDAQ: DRMADermata Therapeutics Inc Stock
$2.04-0.17 (-7.69%)
Updated Dec 23, 2025
DRMA Price
$2.04
Fair Value Price
N/A
Market Cap
$2.09M
52 Week Low
$1.97
52 Week High
$23.70
P/E
0.14x
P/B
0.53x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.28
Operating Cash Flow
-$9M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DRMA Overview
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company developing and commercializing treatments for medical and aesthetic skin conditions. Its lead candidates are DMT310 and DMT410. Known as Dermata Therapeutics, LLC until 2021, the company was founded in 2014 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DRMA's potential to beat the market
- DRMA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DRMA
RankedUnranked of 487
RankedUnranked of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.24 | A | |
| $312.32 | A | |
| $19.51 | A |
Be the first to know about important DRMA news, forecast changes, insider trades & much more!
DRMA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DRMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRMA is good value based on its earnings relative to its share price (0.14x), compared to the US market average (44.94x)
P/E vs Market Valuation
DRMA is good value based on its earnings relative to its share price (0.14x), compared to the US Biotechnology industry average (146.56x)
P/E vs Industry Valuation
DRMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more DRMA due diligence checks available for Premium users.
Valuation
DRMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.14x
Industry
146.56x
Market
44.94x
DRMA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DRMA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DRMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.53x
Industry
5.38x
DRMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.7M
Profit Margin
0%
Assets to liabilities
Assets
$5.1M
Liabilities
$1.1M
Debt to equity
0.28
DRMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
-$13.0k
DRMA vs Biotech Stocks
Dermata Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.